Back to Journals » Infection and Drug Resistance » Volume 15
Intrinsic Resistance: A Significant Characteristic in Evaluating Antibiotic Sensitivity Pattern [Response to Letter]
Authors Woreta AN , Kebede HB , Tilahun Y, Teklegiorgis SGS, Abegaz WE
Received 14 March 2022
Accepted for publication 14 March 2022
Published 7 April 2022 Volume 2022:15 Pages 1625—1626
Asmamaw Nitsuh Woreta,1,2 Habtamu Biazin Kebede,1 Yonas Tilahun,3 Solomon Gebreselassie Teklegiorgis,1 Woldaregay Erku Abegaz1
1Department of Microbiology, Immunology and Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 2Microbiology Unit, Department of Laboratory Sciences, Menelik II Referral Hospital, Addis Ababa, Ethiopia; 3Department of Ophthalmology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
Correspondence: Habtamu Biazin Kebede, Email [email protected]
View the original paper by Mr Woreta and colleagues
This is in response to the Letter to the Editor
Dear editor
We would like to thank the readers and their valuable comments suggested. We have carefully reviewed their comments and responded to each comment one by one as follows.
- This study reported Providencia stuartii as 100% sensitive (only one strain isolated and tested) to Ampicillin and Gentamicin whereas P. stuartii is considered intrinsically resistant to several antibiotics including Ampicillin, Gentamicin, and Tobramycin.2,3 The bacteria with intrinsic resistance to antibiotics should be reported as “Resistant” only.2 Moreover, intrinsic resistance is highly important as it along with another resistance mechanism may result in poor clinical outcomes.4,5
Responses: Thank you for your insightful comments. Notably, Providencia stuartii is a known drug resistance opportunistic pathogen. However, no documented evidence reveals Providencia stuartii is intrinsically resistant to stated antibiotics (Ampicillin, Gentamicin, and Tobramycin). There is a text on CLSI guidelines that stated Providencia stuartii should be considered resistant to gentamicin and tobramycin but not intrinsically resistant to amikacin. This sentence means that if the organism is resistant to ampicillin, Augmentin, cephalosporin I, tetracycline, Nitrofurantoin, Polymyxin, and colistins, the organism should be considered drug-resistant.1–3 This evidence is supported by a recently published work 51.3%, 51.3% of sensitivity for Gentamicin, and Tobramycin among 76 isolates, respectively.4 More than 60% of P. stuartii isolates were found to be sensitive to aminoglycosides (gentamicin, streptomycin, and tobramycin), penicillin (amoxicillin, Augmentin, and ampicillin).5–7 This substantial evidence revealed that P. stuartii is not intrinsically resistant to the aforementioned antibiotics (Ampicillin, Gentamicin, and Tobramycin) at this time.
Responses: Thank you for raising important comments. Oxacillin disk is used as a surrogate antibiotic susceptibility test against penicillin for Streptococcus pneumoniae. Predicts penicillin susceptibility if the oxacillin zone is ≥20 mm with the disc diffusion method. If the oxacillin zone is ≤19 mm, penicillin MIC must be done. As a result, it proposed groupings of antimicrobial agents approved for clinical use and should be considered for testing and reporting on fastidious organisms with disk diffusion method with Oxacillin disk.1–3
NCCLS also recommends that all invasive S. pneumoniae isolates found to be “possibly resistant” to beta-lactams (ie, an oxacillin zone size of less than 20 mm) by oxacillin screening should undergo further susceptibility testing by using a quantitative MIC method acceptable for penicillin, extended-spectrum cephalosporins, and other drugs as clinically indicated.8
Response: Thank you for your comment. We agree that each experiment should be carried out by the CLSI criteria, which were just released. At the time of the data collection, the new version was not available freely. Unless there was a modification in the amended version of the guideline, which did not result in any changes, whether we use the new version or the old one.1–3 This holds true for this particular case.
Disclosure
The authors declare no conflicts of interest in this communication.
References
1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing.
2. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing.
3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing.
4. Liu J, Wang R, Fang M. Clinical and drug resistance characteristics of Providencia stuartii infections in 76 patients. J Int Med Res. 2020;48(10):300060520962296. PMID: 33081537; PMCID: PMC7588764. doi:10.1177/0300060520962296
5. Penner JL, Preston MA. Differences among Providencia species in their in vitro susceptibilities to five antibiotics. Antimicrob Agents Chemother. 1980;18(6):868–871. PMID: 7235674; PMCID: PMC352980. doi:10.1128/AAC.18.6.868
6. Woods TD, Watanakunakorn C. Bacteremia due to Providencia stuartii: a review of 49 episodes. South Med J. 1996;89(2):221–224. PMID: 8578355. doi:10.1097/00007611-199602000-00013
7. Bonfiglio G, Perilli M, Stefani S, Amicosante G, Nicoletti G. Prevalence of extended spectrum beta-lactamases among Enterobacteriaceae: An Italian survey. Int J Antimicrob Agents. 2002;19(3):213–217. PMID: 11932144. doi:10.1016/s0924-8579(01)00497-6
8. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing. Vol. 14. NCCLS document M100-S5. Villanova, PA: National Committee for Clinical Laboratory Standards; 1994.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.